People are watching an earlier-stage treatment – amycretin – even closer. That experimental drug recently showed promising results in a phase 1b/2a trial. Jorgensen said Novo is talking to the ...
Recently, Novo Nordisk revealed trial results for two new obesity drugs, CagriSema and Amycretin. The former disappointed investors with less-than-projected weight loss, resulting in a 20% ...
See the 10 stocks » Novo Nordisk's weight loss candidate in question is called amycretin. The company is developing an oral and a subcutaneous version of this medicine. Amycretin is a GLP-1 ...
Hosted on MSN18d
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its HandsAnd based on the data so far, amycretin looks even more impressive than Wegovy and Eli Lilly's Zepbound, the two top-selling weight loss drugs. In a 72-week study, Zepbound's mean weight loss was ...
Novo Nordisk's weight loss candidate in question is called amycretin. The company is developing an oral and a subcutaneous version of this medicine. Amycretin is a GLP-1 agonist, but it also ...
NVO’s Encouraging Data From the Novel Obesity Drug Study Novo Nordisk announced encouraging data from a phase Ib/IIa study on subcutaneous amycretin, a novel unimolecular GLP-1 and amylin ...
The drugmaker’s shares jumped last Friday after its once-weekly shot of amycretin delivered as much as 22% weight loss in an early trial. That helped soothe investor nerves about Novo’s drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback